Skip to main content
Fig. 6 | BMC Gastroenterology

Fig. 6

From: The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS

Fig. 6

Survival and response analysis of GC patients with high or low TFB. (A and B) Differences in the overall survival (A) and 3-year survival rate (B) between the groups were analyzed by log-rank and Fisher’s exact test (two sided), respectively. (C and D) Differences in disease-specific survival time (C) and 2-year disease Specific survival rate (D) between the groups were analyzed by log-rank and Fisher’s exact test (two sided), respectively. (E and F) Durable clinical benefit (DCB; E) and response (F) analysis with pembrolizumab treatment in the 45 GC patients from ENA (PRJEB25780). Data were analyzed by Fisher test. Significant differences: p < 0.05

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us